Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89,403,587
-
Total 13F shares
-
69,479,485
-
Share change
-
+3,969,056
-
Total reported value
-
$1,789,961,946
-
Put/Call ratio
-
47%
-
Price per share
-
$25.77
-
Number of holders
-
166
-
Value change
-
+$97,223,694
-
Number of buys
-
83
-
Number of sells
-
77
Institutional Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q1 2022
As of 31 Mar 2022,
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) was held by
166 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
69,479,485 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., JANUS HENDERSON GROUP PLC, VANGUARD GROUP INC, MACQUARIE GROUP LTD, BAKER BROS. ADVISORS LP, Deep Track Capital, LP, STATE STREET CORP, and GOLDMAN SACHS GROUP INC.
This page lists
166
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.